NEWS
Trial Suggests New First-line Treatment Option for Slow-growing Lymphomas
Results from a phase III clinical trial conducted in Germany suggest that the standard initial treatment for patients with slow developing (or indolent) types of B-cell lymphoma should be changed.
The trial's lead investigator, Dr. Mathias Rummel of the University Hospital in Giessen, Germany, reported that patients treated with a combination of rituximab (Rituxan) and bendamustine (Treanda) lived significantly longer without their disease progressing and were less likely to experience major toxicities than patients treated with the standard first-line treatment, a four-drug chemotherapy regimen plus the monoclonal antibody rituximab called R-CHOP. Read more > >
Bone Drugs Linked to Fewer Cases of Breast Cancer
Oral bisphosphonates tied to reduced incidence of the disease in separate studiesU.S. Cancer Cases and Deaths Continued to Decline in 2006
Increased screening, reduction in risk factors, and improved treatments contributed to dropNilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
Drug may be an alternative for patients who develop resistance to imatinibAndrogen Deprivation Therapy Linked to Cardiovascular Disease, Diabetes
Researchers urge cautious use, additional research into risk and prevention of side effectsAntioxidant Supplement May Prevent Return of Precancerous Colorectal Growths
Largest reduction seen in halting return of advanced adenomas
COMMENTARY
Director's Update: Modeling a Future without Cancer
Declines continue. When it comes to cancer rates, those two words are always encouraging. In fact, they were the headline attached to most news stories last week reporting the release of the 2009 Report to the Nation on the Status of Cancer. Understanding that this is not just a single year's trend, as the report made clear, but that many cancer rates have been on the decline for more than a decade, is particularly encouraging. Read more > >
Guest Commentary by Dr. Alan G. Thorson: Moving Toward a World with Less Cancer and More Birthdays
The president of the American Cancer Society shares his thoughts about past accomplishments and future efforts in cancer research Read more > >
| Subscribe Now! |
IN DEPTH
Adapting the Science of Supplements and Cancer Prevention
Small clinical trials may provide clues about genetics, biomarkers, and maximizing preventive benefit
Putting Circulating Tumor Cells to the Test
Clinical trials are exploring new ways to use blood in oncology
Featured Clinical Trial: Defining Optimal Therapy for Metastatic and Recurrent Cervical Cancer
What is the best drug combination for metastatic or recurrent cervical cancer?
Cancer Center Profile: St. Jude Children's Research Hospital Comprehensive Cancer Center
This is the nation's only NCI-designated comprehensive cancer center dedicated solely to pediatric cancers
UPDATES
Notes
- Fred Hutchinson Cancer Research Center to Operate NCI's CIS Contact Center
- Application Deadlines Approach for Interagency Oncology Task Force Fellowships
- President's Cancer Panel Examines Race and Cancer Burden
A MESSAGE TO READERS
NCI Cancer Bulletin Publication Break
The NCI Cancer Bulletin will not be published on December 29. However, subscribers will receive via e-mail a list of the 10 most viewed articles from recent months. Our next issue will be released on January 12, when we resume our usual biweekly publication schedule. If you are not yet a subscriber, submit your e-mail address in the subscribe box above.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
